Back to Journals » Journal of Blood Medicine » Volume 2

Review

Role of ofatumumab in treatment of chronic lymphocytic leukemia

       

Authors Veliz, Pinilla-Ibarz J

Published 2 May 2011 Volume 2011:2 Pages 71—77

DOI https://doi.org/10.2147/JBM.S13063

Review by Single anonymous peer review

Peer reviewer comments 2

Download Article [PDF] 


Marays Veliz, Javier Pinilla-Ibarz
H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Abstract: The management of chronic lymphocytic leukemia (CLL) has dramatically improved in the past decade with the addition of anti-CD20 monoclonal antibodies to the treatment armamentarium. Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved in the US and Europe for the treatment of CLL refractory to alemtuzumab and fludarabine. Preclinical data showed improved complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with rituximab. Clinical studies have shown single-agent activity for ofatumumab in CLL and in other low-grade non-Hodgkin's lymphomas. Combination studies are being conducted to enhance the therapeutic efficacy of ofatumumab. This paper reviews some of the key clinical studies that led to approval of ofatumumab, and future directions.

Keywords: ofatumumab, chronic lymphocytic leukemia, efficacy, safety

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]